

AstraZeneca invests \$200M for manufacturing in Australia

10 February 2020 | News

Towards increasing the facility's production capabilities



AstraZeneca has committed \$200 million to the company's manufacturing facility in North Ryde, Sydney, Australia. The investment follows \$100 million announced in 2017 and will go towards increasing the facility's production capabilities, creating 250 jobs and increasing exports to \$4.4 billion over the next four years.

AstraZeneca's Chief Executive Officer, Pascal Soriot said: "This investment will allow us to bring more life-changing respiratory medicines to patients, with asthma and chronic obstructive pulmonary disease."

For more than 60 years AstraZeneca has had a presence in Australia and today the company has evolved into one of the largest manufacturers and exporters of pharmaceuticals in the country. The local North Ryde facility is among the most digitised and innovative in the company's global network, delivering medicines to millions of patients who need them in Australia, the Asia-Pacific region and other global markets.